Covered recipient · General Payments record
STEPHEN V DRESKIN
Allopathic & Osteopathic Physicians Anesthesiology Pain Medicine
General Payments · PY2018–2024
$1,659.40
- Reported across 73 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $698.75 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SCILEX PHARMACEUTICALS INC. | $373.22 | 3 |
| BOSTON SCIENTIFIC CORPORATION | $90.47 | 2 |
| ABBVIE INC. | $83.96 | 4 |
| Medtronic, Inc. | $64.91 | 3 |
| Nalu Medical, Inc. | $48.31 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $20.67 | 1 |
| Abbott Laboratories | $17.21 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $17.21 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125039838 | CMS |
| ABBVIE INC. | $23.34 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103659434 | CMS |
| ABBVIE INC. | $24.74 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103659436 | CMS |
| ABBVIE INC. | $22.00 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103659438 | CMS |
| ABBVIE INC. | $13.88 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103659440 | CMS |
| Boston Scientific Corporation | $45.15 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092467511 | CMS |
| Boston Scientific Corporation | $45.32 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092467513 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $20.67 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146787875 | CMS |
| Medtronic, Inc. | $23.62 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119295097 | CMS |
| Medtronic, Inc. | $23.44 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119295099 | CMS |
| Medtronic, Inc. | $17.85 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119295101 | CMS |
| Nalu Medical, Inc. | $48.31 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133999684 | CMS |
| SCILEX PHARMACEUTICALS INC. | $17.10 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136220574 | CMS |
| SCILEX PHARMACEUTICALS INC. | $17.53 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136249905 | CMS |
| SCILEX PHARMACEUTICALS INC. | $338.59 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136277105 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.